Guideline issued for nonsevere, severe COVID-19 therapy

(HealthDay)—In an evidence-based guideline developed by an international team of physicians, pharmacists, researchers, and patients, published online April 29 in CMAJ, the journal of the Canadian Medical Association, recommendations are presented for the treatment of COVID-19.

Zhikang Ye, Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues developed evidence-based guidelines and recommendations for treating patients with nonsevere and severe COVID-19.

The authors suggest use of corticosteroids for patients with severe COVID-19 and acute respiratory distress syndrome (ARDS); this recommendation was based on indirect evidence. For patients with severe COVID-19 without ARDS, corticosteroids are not suggested. Convalescent plasma is not suggested for patients with severe COVID-19. For patients with nonsevere COVID-19 and for those with severe COVID-19, ribavirin, umifenovir, favipiravir, lopinavir-ritonavir, hydroxychloroquine, interferon-α, and interferon-β are not suggested. All these recommendations are weak.

Source: Read Full Article